Krka DD (FRA:KN8) Valuation Rank


FRA:KN8 Krka DD FRA:KN8
66 GF Score
Price €257.00
GF Value €148.68
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krka DD Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Krka DD Valuation Rank Related Terms

FRA:KN8
66GF Score
Krka DD FRA:KN8
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krka DD (FRA:KN8) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €257.00 is trading 72.9% above its estimated GF Value™ of €148.68. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for FRA:KN8:

  • Valuation Rank:
  • GF Value™: €148.68 vs. price of €257.00 (72.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
66GF Score

Get the complete analysis for FRA:KN8

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.00
Price
€148.68
GF Value